A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 Posted on May 27, 2026July 31, 2026 by Stef Gesuero
LY6G6D targeting with a T cell engager is a promising therapeutic for MSS colorectal cancer Posted on April 21, 2025July 29, 2026 by Stef Gesuero
Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies Posted on November 6, 2024July 29, 2026 by Ryan Sherwood
A CB21-targeted T cell engager is a promising therapeutic for the treatment of colorectal cancer Posted on November 5, 2024July 29, 2026 by Stef Gesuero
Charting the tumor antigen maps drawn by single-cell genomics Posted on December 13, 2021July 24, 2026 by Ryan Sherwood
